Výsledky vyhledávání - "Harsha S. Madapura"

Akademický článek

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Autor: Alena Malyukova, Dorina Ujvari, Elham Yektaei-Karin, Ana Zovko, Harsha S. Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Minori Tamai, Thao T. T. Nguyen, Koshi Akahane, Takeshi Inukai, Leif Stenke, Daniel Salamon

Publikováno v: Cell Death and Disease, Vol 12, Iss 10, Pp 1-13 (2021)

Abstract Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targe

Externí odkaz: https://doaj.org/article/b3f98bbdd0f14217ba00f833de4eaaa3

Zobrazit plný text záznamu

Akademický článek

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors

Autor: Dorina Ujvari, Alena Malyukova, Ana Zovko, Elham Yektaei-Karin, Harsha S Madapura, Marton Keszei, Noemi Nagy, Kourosh Lotfi, Niclas Björn, Jonas Wallvik, Leif Stenke, Daniel Salamon

Publikováno v: OncoImmunology, Vol 11, Iss 1 (2022)

Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival in chronic myeloid leukemia (CML), but residual disease typically persists even after prolonged treatment. Several lines of evidence suggest that TKIs administered to CML patie

Externí odkaz: https://doaj.org/article/692c9e23d3cf44459c340c094d0cbebe

Zobrazit plný text záznamu

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Autor: Harsha S Madapura, Jonas Wallvik, Elham Yektaei-Karin, Niclas Björn, Takeshi Inukai, Koshi Akahane, Leif Stenke, Daniel Salamon, Kourosh Lotfi, Minori Tamai, Ana Zovko, Noémi Nagy, Dorina Ujvari, Marton Keszei, Alena Malyukova, Thao T. T. Nguyen

Publikováno v: Cell Death & Disease
Cell Death and Disease, Vol 12, Iss 10, Pp 1-13 (2021)

Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targeting of B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3739e8162da5baf9e9bd45ce0bffd91d
https://doi.org/10.1038/s41419-021-04154-0

Zobrazit plný text záznamu

DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance

Autor: Sonia Lain, Jacob Grünler, Sergiu-Bogdan Catrina, Juan Zhang, Graciela Terán, Martin E. Rottenberg, Mihaela Popa, Marie Arsenian-Henriksson, Suhas Darekar, Harsha S Madapura, Emmet McCormack, Marcus J.G.W. Ladds, Danai Lianoudaki

Publikováno v: iScience
iScience, Vol 24, Iss 5, Pp 102494-(2021)

Summary Dihydroorotate dehydrogenase (DHODH) is essential for the de novo synthesis of pyrimidine ribonucleotides, and as such, its inhibitors have been long used to treat autoimmune diseases and are in clinical trials for cancer and viral infections

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::294f4f8049eadb62134461752595cffd
https://pubmed.ncbi.nlm.nih.gov/34113829

Zobrazit plný text záznamu

Interferon γ is a strong, STAT1-dependent direct inducer of BCL6 expression in multiple myeloma cells

Autor: Daniel Salamon, Dorina Ujvari, Tomasz Kallas, Harsha S Madapura, Marijke C L Kröhnke, Leif Stenke, Noémi Nagy, Eva Klein

Publikováno v: Biochemical and biophysical research communications. 498(3)

B-cell CLL/lymphoma 6 (BCL6) is a transcriptional master regulator that can repress more than 1200 potential target genes. It exerts oncogenic effects through the inhibition of differentiation, DNA damage sensing and apoptosis in several human hemato

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbacd1ac5f6f51a35a4bbefa7bf8e4fd
https://pubmed.ncbi.nlm.nih.gov/29510136

Zobrazit plný text záznamu

RhoA knockout fibroblasts lose tumor-inhibitory capacity in vitro and promote tumor growth in vivo

Autor: Harsha S Madapura, George Klein, Benedek Bozoky, Kaisa Lehti, Vladimir I. Kashuba, Andrey Alexeyenko, Matthew Fielden, Frida Danielsson, Emma Lundberg, Tatiana V. Pavlova, Martial Balland, S. Pauliina Turunen, Robert Jan Lebbink, Twana Alkasalias, Annica K. B. Gad, Hayrettin Guven, Katharina Hennig

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America, 114(8), E1413
Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2017, 114 (8), pp.E1413-E1421. ⟨10.1073/pnas.1621161114⟩

Fibroblasts are a main player in the tumor-inhibitory microenvironment. Upon tumor initiation and progression, fibroblasts can lose their tumor-inhibitory capacity and promote tumor growth. The molecular mechanisms that underlie this switch have not

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1aded01635c78b847e2aca6d36655bf8
https://pubmed.ncbi.nlm.nih.gov/28174275

Zobrazit plný text záznamu

cMyc-p53 feedback mechanism regulates the dynamics of T lymphocytes in the immune response

Autor: Harsha S Madapura, Sonia Lain, Noémi Nagy, Klas G. Wiman, Daniel Salamon, Eva Klein

Publikováno v: Cell cycle (Georgetown, Tex.). 15(9)

Activation and proliferation of T cells are tightly regulated during the immune response. We show here that kinetics of proliferation of PHA activated T cells follows the expression of cMyc. Expression of p53 is also elevated and remains high several

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d07f9549f5f52121c7ae1635747cde13
https://pubmed.ncbi.nlm.nih.gov/26985633

Zobrazit plný text záznamu

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells

Autor: Harsha S Madapura, S Amu, Noémi Nagy, Dorina Ujvari, Tomasz Kallas, Lisa S. Westerberg, J S McMurray, Leif Stenke, Marton Keszei, Daniel Salamon, F Xue, Eva Klein, Magnus Björkholm, Huimin Cheng, M C L Kröhnke, George Klein, P K Mandal

Publikováno v: Oncogene. 36(32)

B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4dd4b53cff20fba7890bc73464262c0
https://pubmed.ncbi.nlm.nih.gov/28368400

Zobrazit plný text záznamu

Soluble factors produced by activated CD4 + T cells modulate EBV latency

Autor: George Klein, Dorina Ujvari, Frank Heuts, Benjamin Leveau, Monika Adori, Harsha S Madapura, Daniel Salamon, Abu Rasul, Eva Klein, Noémi Nagy

Publikováno v: Proceedings of the National Academy of Sciences. 109:1512-1517

Following infection with Epstein–Barr virus (EBV), the virus is carried for life in the memory B-cell compartment in a silent state (latency I/0). These cells do not resemble the proliferating lymphoblastoid cells (LCLs) (latency III) that are gene

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f48732d546dc96347a9130e114ab7991
https://doi.org/10.1073/pnas.1120587109

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání